EICHORPublic-registry site landscape for NCT03368339, “Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis”, a Allergic Conjunctivitis study sponsored by Realm Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03368339 (registry record) |
| Study title | Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis |
| Official title | Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®) |
| Sponsor | Realm Therapeutics, Inc. |
| Condition(s) | Allergic Conjunctivitis |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03368339.
Eichor generates a preliminary site-risk snapshot for NCT03368339 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Allergic Conjunctivitis trials
← Eichor home · All tracked trials · Allergic Conjunctivitis studies · Weekly briefs
